Thanks. Will take a look after dinner. Meanwhile...
Jan. 31 /PRNewswire/ -- ZymoGenetics, Inc. has appointed James A. Johnson as the new Chief Financial Officer (CFO), the company announced today. Mr. Johnson, who most recently served as Senior Vice President and CFO at Targeted Genetics, brings to ZymoGenetics over 20 years of financial experience. The company also announced the appointments of Shinko Campos to the position of Senior Vice President and Chief Business and Operations Officer, and Charles E. Hart, Ph.D., to the newly created position of Senior Director, Corporate Communications and Investor Relations.
``Jim has established an outstanding financial track record at Targeted Genetics and Immunex,'' said Bruce L.A. Carter, Ph.D., President and Chief Executive Officer of ZymoGenetics. ``His knowledge of financing and his relationships in the biotechnology investment community will be extremely valuable assets to ZymoGenetics as an independent company.''
``Shinko's experience in finance, and her critical involvement in the negotiations that led to ZymoGenetics' independence make her particularly suited to become Senior Vice President of Business and Operations,'' noted Dr. Carter.
Dr. Carter added, ``Charlie Hart has been and remains a key member of our management team. Charlie's input will be critical as we begin to communicate the value of ZymoGenetics' approach to a broader range of people, partners and investors.''
``ZymoGenetics is in a unique position, having recently re-established its independence following the completion of a $150 million private placement,'' said Mr. Johnson. ``The company's ability to raise this substantial sum underscores the investment community's strong support for ZymoGenetics' strategy, namely its focus on the development of protein therapeutics.''
In addition to his work with private and public offerings at Targeted Genetics, Mr. Johnson was instrumental in establishing a joint venture program to advance the company's technology platforms. Previously he served as Vice President of Finance at Immunex Corporation, where he was responsible for the financial operations of the company as it advanced from development stage to full commercial operations. He formerly held positions as Vice President and Controller at Safeco Properties, Inc. and as Senior Auditor at Arthur Young. Mr. Johnson received his B.A. in Business Administration from the University of Washington.
Shinko Campos has held several key positions in business and administration at ZymoGenetics during the past 16 years, and most recently served as Senior Vice President of Finance and Administration. She has played a critical role in several financial transactions, including the purchase and restoration of the historic Lake Union Steam Plant in Seattle, Washington, the current location of ZymoGenetics. Prior to joining ZymoGenetics, Ms. Campos held positions at Spectra Technology and at Ford Motor Company. She received her B.A. in Business Administration from the University of Washington and her MBA in Finance from the University of Puget Sound. Ms. Campos is a CPA in the State of Washington.
Dr. Charles Hart, ZymoGenetics' new head of Corporate Communications and Investor Relations, has played key roles in the company's growth over the past 18 years. Dr. Hart has held various research and development positions within ZymoGenetics, and was critical in advancing much of the company's scientific work in the fields of cell biology and protein chemistry. He most recently served as Senior Director of Business Development and Strategic Planning, with responsibility for many of the company's technology licensing and partnership agreements. Dr. Hart received his B.S. in Zoology from the University of California, Davis; his M.S. in Zoology from Oregon State University; and his Ph.D. in Pathology from the University of Washington.
About ZymoGenetics
ZymoGenetics is an independent biopharmaceutical company focused on the discovery and development of protein therapeutics that prevent or treat significant human diseases. Using a proven product discovery engine, ZymoGenetics has generated a broad pipeline of proprietary product candidates. Through outstanding scientific leadership, ZymoGenetics has established an integrated platform of expertise in genomics, bioinformatics, protein chemistry and cell biology. ZymoGenetics will commercialize protein therapeutics through internal development, collaborations with biopharmaceutical partners and out-licensing of its extensive patent portfolio. ZymoGenetics is headquartered in Seattle, Washington. For further information, visit www.zymogenetics.com. |
